Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

MitoImmune Therapeutics

Request full access

Biotech innovator developing breakthrough therapeutics targeting mitochondrial dysfunction to treat necrotic and inflammatory diseases

Seoul, South KoreaFounded 2018Biotech & Life Sciences

About MitoImmune Therapeutics

MitoImmune Therapeutics Inc. is a biotech company focused on drug discovery and development, leveraging proprietary technology to target mitochondria for creating potential breakthrough therapeutics. The company aims to increase healthy lifespan by addressing mitochondrial dysfunction, which is linked to necrotic and inflammatory diseases. MitoImmune collaborates with leading experts in mitochondria biology and medicine to identify new treatments that enhance mitochondrial function and improve patient quality of life. The company serves a global market, targeting millions of patients suffering from mitochondrial-related conditions. Its business model involves extensive research and development, followed by clinical trials and eventual commercialization of successful therapeutics. Revenue is generated through the sale of these therapeutics, partnerships, and potentially licensing its proprietary technology.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
65.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Sep 2023 $4.4M $115M KGround Partners · BMI Korea ↗
SERIES B✓Equity / VC Apr 2021 $23M $92M BNH Investment · SL Investment ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

MitoImmune Therapeutics website traffic

Latest recorded traffic for MitoImmune Therapeutics is 3K monthly website visits, down 6.3% over the last three months. MitoImmune Therapeutics's team declined 16.7% over the past year.

Latest monthly visits3K 3-month web change-6.3% 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

MitoImmune Therapeutics in the Seoul ecosystem

Live from Dealroom

The MitoImmune Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • KB Investment
  • Korea Development Bank
  • SL Investment
  • BNH Investment

Series B and later2 investors entered at this stage

  • KGround Partners
  • BMI Korea

Other known investors2 additional known investors

  • Aju IB Investment
  • Quantum Ventures Korea
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇰🇷 South Korea100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about MitoImmune Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MitoImmune Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.